Growth Metrics

Gilead Sciences (GILD) Payables (2016 - 2026)

Gilead Sciences filings provide 17 years of Payables readings, the most recent being $715.0 million for Q4 2025.

  • On a quarterly basis, Payables fell 14.17% to $715.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $715.0 million, a 14.17% decrease, with the full-year FY2025 number at $715.0 million, down 14.17% from a year prior.
  • Payables hit $715.0 million in Q4 2025 for Gilead Sciences, down from $808.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $905.0 million in Q4 2022 to a low of $537.0 million in Q2 2024.
  • Median Payables over the past 5 years was $618.0 million (2022), compared with a mean of $662.8 million.
  • Biggest five-year swings in Payables: crashed 83.74% in 2021 and later soared 54.1% in 2024.
  • Gilead Sciences' Payables stood at $705.0 million in 2021, then increased by 28.37% to $905.0 million in 2022, then tumbled by 39.23% to $550.0 million in 2023, then skyrocketed by 51.45% to $833.0 million in 2024, then dropped by 14.17% to $715.0 million in 2025.
  • The last three reported values for Payables were $715.0 million (Q4 2025), $808.0 million (Q3 2025), and $582.0 million (Q2 2025) per Business Quant data.